

**ClinicalTrials.gov Search Results 07/04/2022**

	Title	Status	Study Results	Conditions	Interventions	Locations
1	<a href="#">CapTemY90 for Grade 2 NET Liver Metastases</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Neuroendocrine Tumor Grade 2</li> <li>•Neuroendocrine Tumors</li> </ul>	<ul style="list-style-type: none"> <li>•Drug: Capecitabine Oral Product</li> <li>•Drug: Temozolomide Oral Product</li> <li>•Combination Product: transarterial radioembolization</li> </ul>	<ul style="list-style-type: none"> <li>•CARTI Cancer Center, Little Rock, Arkansas, United States</li> <li>•Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States</li> <li>•University of Pennsylvania, Philadelphia, Pennsylvania, United States</li> </ul>
2	<a href="#">A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent</a>	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Neuroendocrine Tumor Grade 2</li> <li>•Neuroendocrine Tumor Grade 1</li> </ul>	<ul style="list-style-type: none"> <li>•Drug: [203Pb]VMT-#-NET</li> <li>•Device: SPECT/CT</li> </ul>	
3	<a href="#">Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Neuroendocrine Tumors</li> <li>•Neuroendocrine Neoplasm</li> <li>•Neuroendocrine Tumor Grade 1</li> <li>•Neuroendocrine Tumor Grade 2</li> <li>•Neuroendocrine Carcinoma</li> </ul>	<ul style="list-style-type: none"> <li>•Drug: Somatostatin analog; chemotherapy</li> </ul>	<ul style="list-style-type: none"> <li>•Andrea M Isidori, Rome, Italy</li> </ul>
4	<a href="#">Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study</a>	Completed	No Results Available	<ul style="list-style-type: none"> <li>•Poorly Differentiated Malignant Neuroendocrine Carcinoma</li> <li>•Neuroendocrine Carcinoma, Grade 3</li> <li>•Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3</li> <li>•Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3</li> <li>•Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)</li> </ul>	<ul style="list-style-type: none"> <li>•Drug: Everolimus (Afinitor®)</li> </ul>	<ul style="list-style-type: none"> <li>•Charité-Universitätsmedizin, Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Campus Virchow-Klinikum, Berlin, Germany</li> </ul>
5	<a href="#">Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Neuroendocrine Tumors</li> </ul>	<ul style="list-style-type: none"> <li>•Drug: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT</li> <li>•Drug: CAPTEM (Capecitabine and Temozolomide)</li> <li>•Other: Amino-Acid Solution</li> <li>•Drug: Everolimus</li> <li>•Drug: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)</li> </ul>	<ul style="list-style-type: none"> <li>•Washington University Alvin J. Siteman Cancer Center, Saint Louis, Missouri, United States</li> <li>•Memorial Sloan-Kettering Cancer Center, New York, New York, United States</li> <li>•University of Texas MD Anderson Cancer Center, Houston, Texas, United States</li> <li>•Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia</li> <li>•Haut-Leveque Hospital, Department of Hepatogastroenterology and Digestive Tract Oncology, Pessac, Bordeaux, France</li> <li>•Nantes University Hospital Center - Hotel Dieu Hospital, Nantes, Cedex, France</li> <li>•Edouard Herriot Hospital, Medical Oncology Unit, Lyon, France</li> <li>•IUCT Oncopole - Institut Universitaire du Cancer de Toulouse, Toulouse, France</li> <li>•All India Institute Of Medical Sciences, Nuclear Medicine, New Delhi, Delhi, India</li> <li>•HCG Cancer Centre, Medical Oncology, Bangalore, Karnataka, India</li> <li>•and 8 more</li> </ul>

	Title	Status	Study Results	Conditions	Interventions	Locations
6	<a href="#">Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET</a>	Recruiting	No Results Available	•Gastro-enteropancreatic Neuroendocrine Tumor	<ul style="list-style-type: none"> <li>•Drug: Lutathera</li> <li>•Drug: long-acting octreotide</li> <li>•Drug: high dose long-acting octreotide</li> <li>•Other: Optional post-progression re-treatment with Lutathera</li> <li>•Other: Optional post-progression cross-over to Lutathera</li> </ul>	<ul style="list-style-type: none"> <li>•Yale Cancer Center, New Haven, Connecticut, United States</li> <li>•USF - H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States</li> <li>•University of Iowa Hospitals and Clinics - Oncology, Iowa City, Iowa, United States</li> <li>•University of Kentucky UK Markey Cancer Center, Lexington, Kentucky, United States</li> <li>•Mayo Clinic - Oncology, Rochester, Minnesota, United States</li> <li>•Nebraska Cancer Centers, Omaha, Nebraska, United States</li> <li>•MD Anderson Cancer Center, Houston, Texas, United States</li> <li>•A.C.Camargo Cancer Center, Sao Paulo, Brazil</li> <li>•Sociedade Beneficente de Senhoras Hospital Sirio-Libanês, Sao Paulo, Brazil</li> <li>•London Health Sciences Centre, University of Western Ontario - Oncology, London, Canada</li> <li>•and 45 more</li> </ul>
7	<a href="#">Avelumab in G2-3 NET</a>	Unknown status	No Results Available	•Neuroendocrine Tumors	•Drug: Avelumab	•Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
8	<a href="#">Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Neuroendocrine Tumor of Pancreas (Disorder)</li> <li>•Neuroendocrine Tumor Grade 1</li> </ul>	•Procedure: Radiofrequency ablation	•Institut Paoli Calmettes, Marseille, France
9	<a href="#">Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Neuroendocrine Tumors</li> <li>•Neuroendocrine Tumor Grade 3</li> <li>•Neuroendocrine Carcinoma</li> <li>•Neuroendocrine Neoplasm</li> </ul>	<ul style="list-style-type: none"> <li>•Drug: Chidamide</li> <li>•Drug: Sintilimab</li> </ul>	<ul style="list-style-type: none"> <li>•The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China</li> <li>•Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China</li> </ul>
10	<a href="#">Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors</a>	Terminated	Has Results	<ul style="list-style-type: none"> <li>•Small Cell Lung Cancer (SCLC)</li> <li>•Neuroendocrine Tumors</li> </ul>	•Drug: Desipramine HCL	•Stanford University Cancer Institute, Stanford, California, United States
11	<a href="#">Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery</a>	Recruiting	No Results Available	•Gastroenteropancreatic Neuroendocrine Tumor	<ul style="list-style-type: none"> <li>•Drug: Lutathera</li> <li>•Drug: Gallium 68 Dotatate</li> <li>•Procedure: Computed Tomography (CT)</li> <li>•Procedure: Magnetic Resonance Imaging (MRI)</li> <li>•Procedure: PET/CT</li> </ul>	•Stanford Cancer Institute Palo Alto, Stanford, California, United States
12	<a href="#">Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer</a>	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Grade I Neuroendocrine Carcinoma</li> <li>•Grade II Neuroendocrine Carcinoma</li> <li>•Grade III Neuroendocrine Carcinoma</li> <li>•Metastatic Neuroendocrine Carcinoma</li> <li>•Neuroendocrine Carcinoma</li> <li>•Recurrent Small Cell Lung Carcinoma</li> <li>•Refractory Small Cell Lung Carcinoma</li> <li>•Lung Cancer Stage IV</li> <li>•Large Cell Neuroendocrine Carcinoma</li> <li>•Neuroendocrine Tumors</li> <li>•Small Cell Lung Cancer Metastatic</li> <li>•Small-cell Lung Cancer</li> </ul>	<ul style="list-style-type: none"> <li>•Biological: Nivolumab</li> <li>•Drug: Temozolomide</li> </ul>	<ul style="list-style-type: none"> <li>•Ohio State University Comprehensive Cancer Center-COHORT 1, Columbus, Ohio, United States</li> <li>•Ohio State University Comprehensive Cancer Center-COHORT 2, Columbus, Ohio, United States</li> </ul>

	Title	Status	Study Results	Conditions	Interventions	Locations
13	<a href="#">A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers</a>	Completed	Has Results	•Neuroendocrine Tumors	•Drug: fosbretabulin tromethamine	<ul style="list-style-type: none"> <li>•Stanford University School of Medicine, Stanford, California, United States</li> <li>•Markey Cancer Center, Clinical Research Office, Lexington, Kentucky, United States</li> <li>•Montefiore, Bronx, New York, United States</li> <li>•Duke University Medical Center, Durham, North Carolina, United States</li> <li>•Froedtert Hospital, Medicial College of Wisconsin, Milwaukee, Wisconsin, United States</li> </ul>
14	<a href="#">A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System</a>	Terminated	Has Results	•Neuroendocrine Tumors	•Drug: ABI-009	<ul style="list-style-type: none"> <li>•Ochsner Clinic Foundation, New Orleans, Louisiana, United States</li> </ul>
15	<a href="#">TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors</a>	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Neuroendocrine Tumors</li> <li>•Neuroendocrine Carcinoma</li> <li>•Temozolomide</li> <li>•Capecitabine</li> </ul>	•Drug: TEMCAP	<ul style="list-style-type: none"> <li>•Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of</li> </ul>
16	<a href="#">Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study</a>	Completed	No Results Available	•Neuroendocrine Tumors	•Drug: fosbretabulin	<ul style="list-style-type: none"> <li>•Stanford University School of Medicine, Stanford, California, United States</li> <li>•Markey Cancer Center, Clinical Research Office, Lexington, Kentucky, United States</li> <li>•Montefiore, Bronx, New York, United States</li> <li>•Duke University Medical Center, Durham, North Carolina, United States</li> <li>•Froedtert Hospital, Medicial College of Wisconsin, Milwaukee, Wisconsin, United States</li> </ul>
17	<a href="#">Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma</a>	Completed	No Results Available	<ul style="list-style-type: none"> <li>•Neuroendocrine Tumors</li> <li>•Carcinoid Tumor</li> </ul>	•Drug: Quarfloxin	<ul style="list-style-type: none"> <li>•Birmingham Hematology and Oncology, Birmingham, Alabama, United States</li> <li>•Rocky Mountain Cancer Centers, Denver, Colorado, United States</li> <li>•Front Range Cancer Specialists, Fort Collins, Colorado, United States</li> <li>•Ocala, Florida, United States</li> <li>•Southern New Mexico Cancer Center, Las Cruces, New Mexico, United States</li> <li>•Texas Oncology, Amarillo, Texas, United States</li> <li>•Texas Oncology, Dallas, Texas, United States</li> <li>•El Paso Cancer Treatment Center, El Paso, Texas, United States</li> <li>•Cancer Care Centers of South Texas, Kerrville, Texas, United States</li> <li>•UT Health Science Center, San Antonio, Texas, United States</li> <li>•and 3 more</li> </ul>
18	<a href="#">A Study of Pembrolizumab in Patients With Neuroendocrine Tumors</a>	Completed	Has Results	•Neuroendocrine Tumors	•Drug: Pembrolizumab	<ul style="list-style-type: none"> <li>•Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States</li> <li>•MD Anderson Cancer Center, Houston, Texas, United States</li> </ul>
19	<a href="#">Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Schwannomatosis</li> <li>•Pain</li> </ul>	<ul style="list-style-type: none"> <li>•Drug: Tanezumab</li> <li>•Drug: Placebo</li> </ul>	<ul style="list-style-type: none"> <li>•Massachusetts General Hospital, Boston, Massachusetts, United States</li> </ul>

	Title	Status	Study Results	Conditions	Interventions	Locations
20	<a href="#">Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment</a>	Active, not recruiting	Has Results	<ul style="list-style-type: none"> <li>•Locally Advanced or Metastatic Medullary Thyroid Cancer</li> <li>•Medullary Thyroid Cancer</li> </ul>	<ul style="list-style-type: none"> <li>•Behavioral: Patient outreach</li> <li>•Drug: Vandetanib</li> </ul>	<ul style="list-style-type: none"> <li>•Investigational Site Number 301, St Leonards, Australia</li> <li>•Investigational Site Number 401, Wien, Austria</li> <li>•Investigational Site Number 501, Bruxelles, Belgium</li> <li>•Investigational Site Number 701, Porto Alegre, Brazil</li> <li>•Investigational Site Number 702, Ribeirão Preto, Brazil</li> <li>•Investigational Site Number 901, Sofia, Bulgaria</li> <li>•Investigational Site Number 1001, London, Canada</li> <li>•Investigational Site Number 1002, Sherbrooke, Canada</li> <li>•Investigational Site Number 1003, Toronto, Canada</li> <li>•Investigational Site Number 1301, Beijing, China</li> <li>•and 24 more</li> </ul>
21	<a href="#">177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Thyroid Cancer, Medullary</li> <li>•Neuroendocrine Tumor of the Lung Grade 1 and 2</li> <li>•Neuroendocrine Tumor of the Thymus Grade 1 and 2</li> <li>•Neuroendocrine Tumor GEP Grade 1-3</li> </ul>	•Drug: 177Lu-PP-F11N	•University Hospital Basel, Clinic for radiology and nuclear medicine, Basel, Switzerland
22	<a href="#">Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETS</a>	Active, not recruiting	No Results Available	•Gastroenteropancreatic Neuroendocrine Tumor	•Drug: Lanreotide autogel	<ul style="list-style-type: none"> <li>•West China Hospital of Sichuan University, Sichuan, Chengdu, China</li> <li>•The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China</li> <li>•Harbin Medical University Cancer Hospital, Harbin, Helongjiang, China</li> <li>•Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology, Wuhan, Hubei, China</li> <li>•Qilu Hospital Of Shandong University, Jinan, Shandong, China</li> <li>•The First Affiliated Hospital Of Xi'an Jiaotong University, Shanxi, Xi-an, China</li> <li>•The First affiliated hospital of Xiamen University, Fujian, Xiamen, China</li> <li>•The second affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China</li> <li>•The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China</li> <li>•The First Affiliated Hospital of Zhengzhou University, Henan, Zhengzhou, China</li> <li>•and 5 more</li> </ul>
23	<a href="#">Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET</a>	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Small-cell Lung Cancer</li> <li>•Neuroendocrine Carcinoma</li> </ul>	<ul style="list-style-type: none"> <li>•Drug: Iadademstat</li> <li>•Drug: Paclitaxel</li> </ul>	

	Title	Status	Study Results	Conditions	Interventions	Locations
24	<a href="#">Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Locally Advanced Digestive System Neuroendocrine Carcinoma</li> <li>•Locally Advanced Pancreatic Neuroendocrine Carcinoma</li> <li>•Metastatic Digestive System Neuroendocrine Carcinoma</li> <li>•Metastatic Pancreatic Neuroendocrine Carcinoma</li> <li>•Refractory Digestive System Neuroendocrine Carcinoma</li> <li>•Refractory Pancreatic Neuroendocrine Carcinoma</li> <li>•Unresectable Digestive System Neuroendocrine Carcinoma</li> <li>•Unresectable Pancreatic Neuroendocrine Carcinoma</li> </ul>	<ul style="list-style-type: none"> <li>•Drug: Fluorouracil</li> <li>•Drug: Leucovorin</li> <li>•Drug: Liposomal Irinotecan</li> <li>•Procedure: Quality-of-Life Assessment</li> </ul>	<ul style="list-style-type: none"> <li>•Roswell Park Cancer Institute, Buffalo, New York, United States</li> <li>•Stony Brook Cancer Center, Stony Brook, New York, United States</li> </ul>